Familial Breast Cancer

Breast Pathology: A Volume in Foundations in Diagnostic Pathology Series

Volumn , Issue , 2006, Pages 241-248

  Bane, Anita ^a   O'Malley, Frances P ^b,c  

^a MOUNT SINAI HOSPITAL   (Canada)

^b MOUNT SINAI HOSPITAL   (United States)

^c UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84867401053     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06680-1.50028-4     Document Type: Chapter

References (20)

1. Agnarsson BA, Jonasson JG, Bjornsdottir IB, et al. Inherited BRCA2 mutation associated with high grade breast cancer. Breast Cancer Res Treat 1998, 47:121-127.
2. Eisinger F, Jacquemier J, Charpin C, et al. Mutations at BRCA1: the medullary breast carcinoma revisited. Cancer Res 1998, 58:1588-1592.
3. Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. J Natl Cancer Inst 1998, 90:1138-1145.
4. Lidereau R, Eisinger F, Champeme MH, et al. Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer. Cancer Res 2000, 60:1206-1210.
5. Marcus JN, Watson P, Page DL, et al. BRCA2 hereditary breast cancer pathophenotype. Breast Cancer Res Treat 1997, 44:275-277.
6. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10:5367-5374.
7. Osin P, Crook T, Powles T, et al. Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers. Lancet 1998, 351:1487.
8. Osin PP, Lakhani SR The pathology of familial breast cancer: Immuno-histochemistry and molecular analysis. Breast Cancer Res 1999, 1:36-40.
9. Quenneville LA, Phillips KA, Ozcelik H, et al. HER-2/neu status and tumor morphology of invasive breast carcinomas in Ashkenazi women with known BRCA1 mutation status in the Ontario Familial Breast Cancer Registry. Cancer 2002, 95:2068-2075.
10. Turner N, Tutt A, Ashworth A Hallmarks of 'BRCAness' in sporadic cancers. Nature Rev Cancer 2004, 4:814-819.
11. Foulkes WD BRCA1 functions as a breast stem cell regulator. J Med Genet 2004, 41:1-5.
12. Hedenfalk I, Ringner M, Ben-Dor A, et al. Molecular classification of familial non-BRCA1/BRCA2 breast cancer. Proc Natl Acad Sci USA 2003, 100:2532-2537.
13. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA 2003, 100:8418-8423.
14. Tavassoli FA, Devilee P Pathology and Genetics of Tumours of the Breast and Female Genital Organs. World Health Organisation of Classification of Tumours 2003, IARC Press, Lyon.
15. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002, 347:1999-2009.
16. Chung MA, Cady B Surgical treatment planning in newly diagnosed breast cancer patients at high risk for BRCA-1 or BRCA-2 mutation. Breast J 2004, 10:473-474.
17. Eisinger F, Charafe-Jauffret E, Jacquemier J, et al. Tamoxifen and breast cancer risk in women harboring a BRCA1 germline mutation: computed efficacy, effectiveness and impact. Int J Oncol 2001, 18:5-10.
18. Hartmann LC, Sellers TA, Schaid DJ, et al. Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. J Natl Cancer Inst 2001, 93:1633-1637.
19. King MC, Wieand S, Hale K, et al. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. J Am Med Assoc 2001, 286:2251-2256.
20. Rebbeck TR, Lynch HT, Neuhausen SL, et al. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002, 346:1616-1622.